Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
AlloVir
Biotech
Reeling from triple phase 3 failure, AlloVir cuts 95% of staff
Less than a month after AlloVir suffered a triple phase 3 failure, the allogeneic T cell immunotherapy biotech is cutting 95% of its workforce.
Annalee Armstrong
Jan 5, 2024 8:53am
Triple phase 3 disaster sends AlloVir shares plunging 64%
Dec 22, 2023 9:00am
Moderna taps Life Edit to develop next-gen gene therapies
Feb 22, 2023 7:00am
AlloVir's cell therapy tackles virus in kidney transplant trial
Feb 15, 2023 9:45am
GSK cuts Slaoui ties over harassment claims—Chutes & Ladders
Mar 26, 2021 9:30am
Gilead's virology lead Brainard jumps ship to AlloVir
Mar 23, 2021 7:25am
